Established in 1967 and headquartered in Yongin, South Korea, GC Biopharma (formerly Green Cross Corporation) is a leading global biopharmaceutical company. With over 55 years of experience, the company has been at the forefront of producing life-saving therapies and vaccines, contributing significantly to both domestic and international healthcare. As a subsidiary of Green Cross Holdings, GC Biopharma operates with a strong commitment to innovation, quality, and patient care.

The company is renowned for its expertise in plasma-derived products, recombinant therapies, and vaccines, addressing critical medical needs across various therapeutic areas. GC Biopharma's global presence includes operations in the United States, China, and Canada, with a robust distribution network spanning over 50 countries. The company's dedication to research and development has led to the creation of several pioneering treatments, including the world's second treatment for Hunter syndrome and the first recombinant antihemophilic drug in Korea.

Key Products and Services

• Alyglo: An FDA-approved intravenous immunoglobulin (IVIG) product, offering enhanced purity and reduced risk of serious bacterial infections.
• I.V.-Globulin SN 5%: A widely used IVIG formulation, distributed in more than 30 countries, providing essential immune support for patients with primary immunodeficiencies.
• Hunterase: A treatment for Hunter syndrome (Mucopolysaccharidosis II), addressing a rare and serious genetic disorder.
• GC Flu Quadrivalent: A seasonal influenza vaccine, prequalified by the World Health Organization (WHO), and a leading supplier to global health initiatives.
• Barycela: The world's first antibiotic-free varicella (chickenpox) vaccine, offering improved stability and safety profiles.
• Contract Manufacturing Services: Providing aseptic fill and finish services for vaccines, recombinant proteins, and biosimilars, leveraging state-of-the-art facilities and expertise.

GC Biopharma continues to drive advancements in biopharmaceuticals, focusing on enhancing patient outcomes through innovative therapies and vaccines. With a strong foundation in research and development, the company remains dedicated to addressing global health challenges and expanding access to essential medicines worldwide.